Pharmaceutical - Mergers & Acquisitions, Oncology

Filter

Popular Filters

1 to 25 of 60 results

MedImmune to acquire company to strengthen focus on biomarkers in immuno-oncology

MedImmune to acquire company to strengthen focus on biomarkers in immuno-oncology

04-11-2014

MedImmune, a US subsidiary of Anglo-Swedish pharma major AstraZeneca has entered into an agreement to…

AstraZenecaDefiniensMedImmuneMergers & AcquisitionsOncologyPharmaceutical

Oxford BioMedica enters LentiVector collaboration with Novartis

Oxford BioMedica enters LentiVector collaboration with Novartis

10-10-2014

UK-based Oxford BioMedica says that it has signed further contracts with Swiss pharma giant Novartis,…

GlobalLentiVectorLicensingMergers & AcquisitionsNovartisOncologyOxford BioMedicaPharmaceutical

Tau Therapeutics and Xdynia merge to form Cavion

29-08-2014

Privately-held US drugmakers Tau Therapeutics and Xdynia announced today that they have merged; the surviving…

CavionMergers & AcquisitionsNeurologicalOncologyPharmaceuticalTau TherapeuticsXdynia

Kyowa Hakko to acquire Archimedes for £230 million

Kyowa Hakko to acquire Archimedes for £230 million

11-07-2014

Through its Scotland-based subsidiary ProStrakan Group, Japanese drugmaker Kyowa Hakko Kirin has entered…

ArchimedesArchimedes PharmaBusiness FinanceDriverHealth Medical PharmaKyowa Hakko KirinMergers & AcquisitionsNeurologicalNovo A/SOncologyPharmaceuticalPharmaceutical industryProStrakanUK

MabVax Therapeutics and Telik close merger

MabVax Therapeutics and Telik close merger

09-07-2014

USA-based MabVax Therapeutics, a privately held cancer immunotherapy company, and Telik, a publicly-traded…

MabVax TherapeuticsMergers & AcquisitionsOncologyPharmaceuticalTelikUSA

SillaJen changes its name to mark Jennerex acquisition

20-06-2014

South Korean privately held pharma company SillaJen has changed its name to SillaJen Biotherapeutics…

Asia-PacificJennerexManagementMergers & AcquisitionsOncologyPexa-VecPharmaceuticalSillaJen

Pfizer inks multi-million $ cancer immunology deal with Cellectis

Pfizer inks multi-million $ cancer immunology deal with Cellectis

18-06-2014

France-based genome engineering specialist Cellectis saw its shares rocket nearly 50% to 9.26 euros,…

CellectisLicensingMergers & AcquisitionsOncologyPfizerPharmaceutical

Celsion to acquire nucleic acid-based therapeutics firm EGEN

Celsion to acquire nucleic acid-based therapeutics firm EGEN

10-06-2014

US cancer drug developer Celsion Corp has entered into a definitive asset purchase agreement with EGEN,…

CelsionEGENMergers & AcquisitionsOncologyPharmaceutical

AstraZeneca stresses confidence in independence, highlighting strong R&D pipeline

15-05-2014

Anglo-Swedish pharma major AstraZeneca, the subject of the controversial takeover attempt by Pfizer,…

AstraZenecaCardio-vascularMergers & AcquisitionsMetabolicsOncologyPharmaceuticalResearchRespiratory and Pulmonary

Riemser Pharma acquires French drugmaker Keocyt

12-05-2014

German specialty pharmaceutical company Riemser Pharma (formerly Riemser Arzneimittel) said today that…

KeocytMergers & AcquisitionsOncologyPharmaceuticalRare diseasesRiemser Pharma

AstraZeneca says Pfizer offer “very significantly” undervalues the firm

28-04-2014

Confirming a takeover approach from the US drugs giant, Anglo-Swedish pharma major AstraZeneca issued…

AstraZenecaMergers & AcquisitionsOncologyPfizerPharmaceutical

BioAlliance Pharma and Topotarget merge to create leader in orphan oncology diseases

BioAlliance Pharma and Topotarget merge to create leader in orphan oncology diseases

16-04-2014

French orphan drug developer BioAlliance Pharma and Denmark’s Topotarget today announced their intention…

belinostatBioAlliance PharmaLivatagMergers & AcquisitionsOncologyPharmaceuticalRare diseasesTopotarget

Five Prime rockets on immuno-oncology deal with Bristol-Myers Squibb

Five Prime rockets on immuno-oncology deal with Bristol-Myers Squibb

17-03-2014

Shares of Five Prime Therapeutics leapt 15% to $21.48 in early trading, after the company said it has…

Bristol-Myers SquibbFive Prime TherapeuticsLicensingMergers & AcquisitionsOncologyPharmaceutical

UK cancer drug companies combine expertise in merger

UK cancer drug companies combine expertise in merger

13-03-2014

UK oncology company Incanthera says it has acquired Onco-NX, the University of Salford drug discovery…

IncantheraMergers & AcquisitionsOnco-NXOncologyPharmaceutical

Way clear for Bayer to complete Algeta acquisition

26-02-2014

The way is now clear for Germany’s Bayer to acquire Norwegian pharmaceutical company Algeta, under…

AlgetaBayerMergers & AcquisitionsOncologyPharmaceuticalXofigo

Novo Nordisk ups stake in Innate Pharma along with sale of anti-NKG2A

Novo Nordisk ups stake in Innate Pharma along with sale of anti-NKG2A

07-02-2014

Danish insulin giant Novo Nordisk has sold full development and commercialization rights to the anti-NKG2A…

anti-NKG2AInnate PharmaLicensingMergers & AcquisitionsNovo NordiskOncologyPharmaceutical

Medigene’s buy of Trianta is “lucrative move” say analysts

31-01-2014

Medigene’s 4 million euro ($5.5 million) purchase of fellow German company Trianta Immunotherapies…

FinancialImmunologicalsMedigeneMergers & AcquisitionsOncologyPharmaceuticalTrianta ImmunotherapiesUSA

Medigene acquires Trianta Immunotherapies

27-01-2014

Germany’s Medigene this morning revealed that it has acquired 100% of the shares of the Munich-based…

MedigeneMergers & AcquisitionsOncologyPharmaceuticalTrianta ImmunotherapiesVaccines

Moderna spins-out Onkaido Therapeutics to focus on mRNA therapeutics in oncology

15-01-2014

Flush with cash as a result of its mega-million dollar deal with Alexion on the development of drugs…

Mergers & AcquisitionsModerna TherapeuticsOncologyOnkaido TherapeuticsPharmaceuticalResearch

Eddingpharm acquires global rights to oncology assets, including telatinib, from ACT Biotech

08-01-2014

Chinese drug firm Eddingpharm has entered into an asset purchase agreement (APA) with a private, venture…

ACT BiotechEddingpharmMergers & AcquisitionsOncologyPharmaceuticaltelatinib

Probiodrug sells its CDK9 inhibitor program to AstraZeneca

Probiodrug sells its CDK9 inhibitor program to AstraZeneca

06-01-2014

Privately-held German company Probiodrug says it has transferred its experimental cyclin-dependent kinase…

AstraZenecaInflammatory diseasesMergers & AcquisitionsOncologyPharmaceuticalProbiodrug

Bayer confirms plans to acquire Norway’s Algeta

Bayer confirms plans to acquire Norway’s Algeta

19-12-2013

German drugs and chemicals major Bayer has officially announced its intention to acquire Norwegian pharmaceutical…

AlgetaBayerGermanyMergers & AcquisitionsNorwayOncologyPharmaceuticalXofigo

Norway’s Algeta confirms takeover bid approach from Bayer

Norway’s Algeta confirms takeover bid approach from Bayer

26-11-2013

In response to recent media commentary, the board of directors of Norway’s Algeta this morning confirmed…

AlgetaBayerMergers & AcquisitionsNorwayOncologyPharmaceuticalXofigo

Imugene to acquire Biolife Sciences

24-10-2013

Australian drug development and pharmaceutical company Imugene says it has executed a sale and purchase…

Asia-PacificMergers & AcquisitionsOncologyPharmaceutical

1 to 25 of 60 results

Back to top